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5,6-Dimethylxanthenone-4-acetic acid, synthesised in this laboratory, reduces tumour blood ﬂow, both in mice and in patients
on Phase I trial. We used TUNEL (TdT-mediated dUTP nick end labelling) assays to investigate whether apoptosis induction
was involved in its antivascular effect. 5,6-Dimethylxanthenone-4-acetic acid induced dose-dependent apoptosis in vitro in
HECPP murine endothelial cells in the absence of up-regulation of mRNA for tumour necrosis factor. Selective apoptosis of
endothelial cells was detected in vivo in sections of Colon 38 tumours in mice within 30 min of administration of 5,6-
Dimethylxanthenone-4-acetic acid (25 mg kg
71). TUNEL staining intensiﬁed with time and after 3 h, necrosis of adjacent
tumour tissue was observed. Apoptosis of central vessels in splenic white pulp was also detected in tumour-bearing mice but
not in mice without tumours. Apoptosis was not observed in liver tissue. No apoptosis was observed with the inactive
analogue 8-methylxanthenone-4-acetic acid. Positive TUNEL staining of tumour vascular endothelium was evident in one
patient in a Phase I clinical trial, from a breast tumour biopsy taken 3 and 24 h after infusion of 5,6-Dimethylxanthenone-4-
acetic acid (3.1 mg m
72). Tumour necrosis and the production of tumour tumour necrosis factor were not observed. No
apoptotic staining was seen in tumour biopsies taken from two other patients (doses of 3.7 and 4.9 mg m
72). We conclude
that 5,6-Dimethylxanthenone-4-acetic acid can induce vascular endothelial cell apoptosis in some murine and human tumours.
The action is rapid and appears to be independent of tumour necrosis factor induction.
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DMXAA (5,6-dimethylxanthenone-4-acetic acid), a new anticancer
agent synthesised in this laboratory (Rewcastle et al, 1991), has
recently completed Phase I clinical trial as an antivascular agent.
In preclinical studies, DMXAA was particularly effective against
transplantable murine tumours with an established vasculature
(Rewcastle et al, 1991), where it caused cessation of tumour blood
ﬂow, vascular collapse and tumour necrosis (Zwi et al, 1994a; Lash
et al, 1998). DMXAA increased tumour necrosis factor (TNF)
concentrations in plasma of both tumour bearing and non-tumour
bearing mice (Philpott et al, 1995). It induced TNF synthesis in
both host and tumour cells of Colon 38 tumours (Joseph et al,
1999) and also induced signiﬁcant amounts of TNF in murine
Colon 38 tumours implanted in TNF knockout mice (Ching et
al, 1999). DMXAA also induced TNF synthesis in host cells, and
in some cases tumour cells, of a series of human tumour xenografts
(Joseph et al, 1999). Co-administration of anti-TNF antibody
together with DMXAA partially reversed the blood ﬂow inhibition
and antitumour action of DMXAA, suggesting that TNF plays a
role in its antivascular effects (Browne et al, 1998).
In contrast to the large increases in plasma TNF observed in
mice treated with DMXAA, plasma TNF levels in patients treated
in a Cancer Research UK phase I trial were not elevated (Jameson
et al, 2000). However, dynamic contrast-enhanced magnetic reso-
nance imaging suggested that tumour blood ﬂow was inhibited
in most patients receiving DMXAA at doses of 500 mg m
72 or
higher (Rustin et al, 1998). These studies suggested that at least
some of the antivascular effects of DMXAA might be independent
of plasma TNF production and result from a direct effect on
tumour vasculature. In this report, we have searched for direct
evidence of such an effect, using both in vitro and in vivo murine
models and tumour biopsies from three patients treated with
DMXAA in a Phase I trial.
MATERIALS AND METHODS
Materials
DMXAA was synthesised in this laboratory (Rewcastle et al, 1991)
and dissolved in 5% sodium bicarbonate for intraperitoneal injec-
tion into mice (25 mg kg
71) in a volume of 0.01 ml g
71 body
weight. DMXAA was dissolved directly in culture medium for in
vitro experiments. In the clinical phase trial conducted in Auck-
land, New Zealand, DMXAA was administered as a 20 min
intravenous infusion on a 3-weekly schedule, using a pre-formu-
lated solution of 20 mg ml
71 in 0.1 M phosphate buffer at
pH 7.7 (Jameson et al, 2000).
Mouse studies
Athymic or normal C57Bl/6 mice were from the Animal Labora-
tories, University of Auckland School of Medicine. All mice were
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www.bjcancer.commaintained under constant temperature and humidity according to
institutional ethical guidelines and used between 8–12 weeks of
age. All animal experiments have been carried out with ethical
committee approval. The ethical guidelines that were followed meet
the standards required by the UKCCCR guidelines (Workman et al,
1998). Colon 38 tumour fragments (1 mm
3) were implanted
subcutaneously in the left ﬂank of anaesthetised (sodium pentobar-
bitone, 86 mg kg
71) normal C57Bl/6 mice. Tumours were used
when they had reached approximately 6 mm in diameter, generally
9–10 days after implantation. Three mice were used for each time
point and treatment, and 2–4 cryosections per organ per mouse
were immunostained for apoptosis using TUNEL.
Clinical studies
Three patients with superﬁcial tumours (two with chest wall
recurrence of breast adenocarcinoma and one with subcutaneous
ovarian adenocarcinoma tumour nodules) consented to biopsies.
These samples were taken prior to infusion of DMXAA then at
various intervals afterwards and were embedded (OCT
compound, a mixture of water-soluble glycols and resins,
Tissue-Tek
1, Sakura Finetech, Torrance, CA, USA) and snap-
frozen. Representative cryosections were immunostained for
apoptosis using TUNEL.
In vitro studies
The HECPP murine endothelial cell line derived from endothelial
cells isolated from murine Peyer’s patches (Bizouarne et al, 1993)
was maintained in M199 media (Gibco BRL) with antibiotics
and 10% foetal calf serum at 378C under humidiﬁed atmosphere
of 5% CO2. Sub-conﬂuent cultures (that had been passaged the
previous day) were incubated with DMXAA for the appropriate
time. The supernatant containing non-adherent cells was removed
and centrifuged at 3006g for 10 min. Adherent cells were lifted
from the dishes by trypsinisation and collected similarly. Combined
adherent and supernatant cells, resuspended in culture medium
(0.4 ml), were used to prepared cytospin preparations that were
assayed for apoptosis.
Apoptosis assay
Apoptosis was determined using the TUNEL assay for identiﬁca-
tion of double-stranded DNA breaks using an In Situ Cell Death
Detection Kit (Boehringer Mannheim) according to manufac-
turer’s instructions. Tissue and tumour cryosections or
cytospots of cells on poly-L-lysine-treated slides were ﬁxed in
4% paraformaldehyde for 30 min at room temperature, washed
with PBS (phosphate buffered saline) and then treated with
permeabilisation solution (0.1% Triton X-100 in 0.1% sodium
citrate) for 2 min on ice. Strand breaks were labelled with ﬂuor-
esceinated dUTP and visualised following reaction with
phosphatase-conjugated antibody to ﬂuorescein and Vector
1
Black alkaline phosphatase substrate solution (Vector Labora-
tories, Burlingame, CA, USA). All slides were counter stained
using methyl green.
Cryosections of Colon 38 tumour tissues were also stained for
endothelial cells to differentiate between apoptosis of the
endothelium and apoptosis of tumour cells. Sections were ﬁrst
processed for apoptosis as described and then immunostained
for endothelial cells using a rat anti-mouse CD-31 antibody
(MEC 13.3, a generous gift from Dr A Vecchi, Instituto di
Rierche Farmacologie Mario Negri, Via Eritrea, Milan, Italy)
(Vecchi et al, 1994), followed by incubation with biotinylated
anti-rat IgG secondary antibody (Vector Laboratories, Burlin-
game, CA, USA) and the avidin-biotin complex (Vectastain
1
ABC-AP Kit). Immunoglobulin complexes were visualised using
Vector
1 Red alkaline phosphatase substrate solution.
Northern blot analysis
Total cellular RNA was extracted using RNAzol (Gibco, BRL)
according to manufacturer’s instructions. RNA (10 mg) was dena-
tured and electrophoresed in 1% agarose-formaldehyde gels as
previously described (Ching et al, 1994). RNA was then transferred
by capillary action onto nylon membrane (Hybond-N
+, Amer-
sham). The membranes were UV-crosslinked (120 mJoule, UV-
Stratalinker, Stratagene, San Diego, CA, USA) and baked (808C
for 30 min). Each membrane was prehybridised (2 h, 428C) in
7 ml hybridisation mix containing 50% formamide, 0.075 M
sodium chloride, 0.05 M sodium dihydrogen phosphate, 5 mM
EDTA, 0.001% polyvinyl pyrrolidone, 0.001% bovine serum albu-
min, 0.001% Ficoll, 0.01 mg ml
71 herring sperm DNA, and
0.5% SDS (sodium dodecyl sulphate). The cDNA to the cytokine
gene of interest was labelled with a
32P-dCTP (Amersham) using
a random priming kit (RTS Radprime DNA labelling system, Gibco
BRL). Excess radioactivity was removed by elution through a G-50
Sephadex column and labelled probe (10
6 c.p.m. ml
71 hybridisa-
tion mix) was then added to the membrane and hybridised for
36 h at 428C. The blots were washed twice in 26SSC (standard
saline citrate) with 0.1% SDS for 10 min at 428C, and ﬁnally in
0.26SSC with 0.1% SDS for 10 min at 658C. Blots were exposed
to X-ray ﬁlm for 1–3 days at 7708C. After hybridisation with
one probe, membranes were stripped (two washes in 300 ml
0.16SSC with 1% SDS for 15 min at 808C) and re-hybridised with
another probe. The signal intensity was quantitated by laser densi-
tometric scanning. Loading of lanes was determined from the
intensity of bands hybridised with the probe for glyceraldehyde-
3-phosphate dehydrogenase (GADPH).
RESULTS
Induction of endothelial cell apoptosis in murine tissues
following DMXAA
Sections of Colon 38 tumours, removed at different times from
C57Bl/6 mice administered DMXAA at its maximum tolerated
dose (25 mg kg
71), were double stained for apoptosis and for
CD31expression (Table 1). As early as 30 min after treatment,
faint apoptotic staining above background staining of untreated
controls (Figure 1A) was detected and found to be associated
with the endothelial cells in the Colon 38 tumour (Figure 1B).
The staining intensity, as well as the number of apoptotic
vessels, increased progressively with time after treatment (Table
1). Up to 3 h after treatment, apoptosis was associated only with
the tumour vascular endothelium, with no apoptosis of tumour
cells (Figure 1B,C). Colon 38 sections taken 3 h after DMXAA
administration contained intensely stained apoptotic vessels,
and at this time, large areas of necrosis of the tumour were
observed (Figure 1D). Following the maximal tolerated dose of
DMXAA, 69% of the vessels in the tumour were apoptotic,
while after a dose of 15 mg kg
71, 27% were apoptotic. Signiﬁ-
cant apoptosis of vessels was not observed following DMXAA
doses of 5 or 10 mg kg
71 (Table 1). Colon 38 tumour sections
removed from mice 3 h after treatment with an inactive analo-
gue, 8-MeXAA (8-methylxanthenone-4-acetic acid) at its
maximal tolerated dose (220 mg kg
71) showed no apoptotic
vessels or tumour necrosis (Figure 1E; Table 1). No staining
was observed with liver sections from either normal or
tumour-bearing mice, before or 3 h after DMXAA (25 mg kg
71)
(Figure 1F). Strong staining for apoptosis was observed in the
central vessel in the white pulp regions of spleens from all
tumour-bearing mice 3 h after DMXAA (Figure 1G), and was
not present without treatment. Apoptosis in the splenic vascula-
ture was tumour-dependent, since apoptotic cells were not
observed in spleens from normal mice following DMXAA
administration (Figure 1H).
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DMXAA
Tumour biopsies from one patient with breast adenocarcinoma
prior to DMXAA infusion (3.1 mg m
72) did not stain with the
TUNEL assay (Figure 1I). However apoptotic staining in vessels
was seen in the biopsy taken 3 h post-infusion (Figure 1J) and
the number of apoptotic vessels increased three-fold in the biopsy
taken after 24 h (Figure 1K; Table 1). In contrast with the murine
3 h samples, haemorrhagic necrosis was not observed. In another
two patients administered DMXAA at 3.7 and 4.9 mg m
72 no
staining for apoptosis was seen in samples taken prior to drug infu-
sion nor in breast carcinoma samples taken at 3 and 24 h or
ovarian carcinoma samples taken at 4.5 h.
DMXAA induces HECPP endothelial cell apoptosis in
culture
We used the murine endothelial HECPP cell line (Bizouarne et
al, 1993) to determine whether DMXAA could induce apoptosis
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Table 1 Quantitation of apoptotic vessels following DMXAA treatment
Tumour/treatment Dose Time n
a
Apoptotic vessels
(percentage)
b
Apoptotic vessels
per ﬁeld
c
Colon 38
Untreated 6 3.7+1.5 0.33+0.21
DMXAA 25 mg kg
71 30 min 13 32+2( P50.001) 1.8+0.3 (P50.01)
DMXAA 25 mg kg
71 1 h 14 30+4( P50.001) 1.5+0.2 (P50.05)
DMXAA 25 mg kg
71 3h 8 6 8 +8( P50.001) 3.1+0.8 (P50.05)
DMXAA 15 mg kg
71 3 h 10 27+3( P50.001) 1.5+0.2 (P50.01)
DMXAA 10 mg kg
71 3h 7 1 1 +4 0.57+0.20
DMXAA 5 mg kg
71 3h 7 1 0 +5 0.57+0.20
8-MeXAA 220 mg kg
71 3 h 2 1.8+1.2 0.33+0.20
Human breast
Pre-treatment 4 N.D.
d 0.0+0.0
DMXAA 3.1 mg m
72 3 h 4 N.D. 3.5+0.9 (P50.001)
DMXAA 3.1 mg m
72 24 h 7 N.D. 9.1+0.5 (P50.001)
aNumber of ﬁelds scored from different sections taken from 2–4 Colon 38 tumour-bearing mice or from the
human tumour sections.
bPercentage of Colon 38 tumour vessels positive for the TUNEL assay. The total
number of vessels was determined by staining with anti-CD-31 antibody. Mean+s.e.m. Signiﬁcance of
difference from control is shown where P50.05 (Student’s t-test).
cNumber of TUNEL-stained vessels per
1m m
2 ﬁeld, counted at 206 magniﬁcation. Mean+s.e.m. from Colon 38 tumour sections or from human
breast carcinoma biopsies from the same patient before and after treatment with DMXAA. Signiﬁcance of
difference from control is shown where P50.05 (Student’s t-test).
dNot determined, since human tumour
sections were not double-stained with anti-CD31 antibodies to quantitate the total number of vessels.
Figure 1 Induction of endothelial cell apoptosis by DMXAA. (A–E) Representative cryosections of Colon 38 tumours (1006 magniﬁcation) were im-
munostained for apoptosis using TUNEL (black) and endothelial cells with antibodies to CD-31 (red): (A) untreated, (B) 30 min after DMXAA
(25 mg kg
71), (C) 1 h after DMXAA, (D) 3 h after DMXAA, (E) 3 h after 8-MeXAA (220 mg kg
71). (F–H) Representative cryosections (1006 mag-
niﬁcation) immunostained for apoptosis using TUNEL (black): (F) liver tissue from Colon 38 tumour-bearing mice 3 h after DMXAA (25 mg kg
71), (G)
spleen tissue from Colon 38-bearing mice 3 h after DMXAA (25 mg kg
71), and (H) spleen tissue from normal mice 3 h after DMXAA (25 mg kg
71). (I–
L) Representative cryosections (1006 magniﬁcation) from a human breast carcinoma immunostained for apoptosis using TUNEL (black): (I) before treat-
ment, (J) 3 h after DMXAA infusion (3.1 mg m
72), (K) 24 h after DMXAA. (L) Section at higher magniﬁcation (5006) of two vessels 3 h after DMXAA
infusion.
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blot analyses, DMXAA does not induce mRNA for TNF or inter-
ferons in the HECPP cells (Figure 2A). Of the cytokine genes
that are up-regulated in mice following DMXAA treatment
(Figure 2B), only mRNA for IP-10 was up-regulated following
2 h incubation with DMXAA at 400 mgm l
71 in the HECPP cells
(Figure 2A). HECPP cells treated with DMXAA were processed
using TUNEL assays and the percentages of apoptotic cells were
determined by counting at least 500 cells. Following exposure to
DMXAA at a concentration (400 mgm l
71) that is achievable in
vivo after administration of an effective antitumour dose (McKe-
age et al, 1991), apoptotic cells were seen after 6 h incubation,
and the numbers increased with prolonged exposure (Figure
3A). Apoptotic cell numbers at 24 h increased linearly with
increasing dose of DMXAA above 100 mgm l
71. The DMXAA
concentration that induced 50% apoptosis after incubation for
24 h was 500 mgm l
71 (Figure 3B).
DISCUSSION
These results are the ﬁrst to demonstrate the selective induction
of endothelial cell apoptosis in both a murine tumour (Figure
1B–D) and a human tumour (Figure 1J–L) following treatment
with DMXAA. Loss of tumour vascular endothelial cells by apop-
tosis would be expected to increase the permeability of the
vascular endothelium, providing a potential mechanism for
reduction in tumour blood ﬂow (Baguley, 2001) as demonstrated
in both murine models (Zwi et al, 1994a,b; Lash et al, 1998) and
in clinical studies (Rustin et al, 1998). The results also provide a
possible mechanism for the DMXAA-induced extravasation of
erythrocytes in murine tumours (Zwi et al, 1994b). Although a
number of studies have implicated TNF in the antitumour
response of DMXAA (Browne et al, 1998; Cao et al, 1999), three
observations in this study support a TNF-independent action of
DMXAA on the vascular endothelium. Firstly, apoptosis of
endothelial cells was observed in Colon 38 tumour sections with-
in 30 min after administration, well before the time at which
TNF is detectable in plasma or tumour tissue (Joseph et al,
1999). Secondly, in the patient where apoptosis was induced in
tumour vessels following treatment with DMXAA, no TNF
induction was detectable in tumour tissue or plasma (Jameson
et al, 2000). Thirdly, apoptosis was induced with increasing
concentrations of DMXAA in HECPP cells in culture (Figure
3) when the cells did not produce TNF (Figure 2A). Of all
the cytokine genes that are known to be induced in vivo by
DMXAA in murine tissues (Cao et al, 2001), only mRNA for
IP-10 was up-regulated in cultures of HECPP cells (Figure 2A).
IP-10 is known for its chemotactic (Luster et al, 1985; Taub et
al, 1993) and anti-angiogenic activities (Angiolillo et al, 1995)
but has no reported apoptotic activity. Our results here suggest
that DMXAA may have a direct apoptotic effect on endothelial
cells.
The induction of endothelial apoptosis in tumour tissue by
DMXAA is not completely tumour-selective. While no apoptosis
was observed in sections from liver of normal or tumour-bearing
mice (Figure 1E), apoptotic cells were detected in the vasculature
of spleens from tumour-bearing animals (Figure 1G). Since such
cells were not observed in spleens of normal mice (Figure 1H),
the tumour appears to sensitise endothelial cells in spleen, but
not liver, to apoptosis induction by DMXAA. A possible reason
for this is that factors released from tumours activate spleno-
cytes, which then react to DMXAA by releasing TNF, thus
inducing endothelial cell apoptosis and reducing splenic blood
ﬂow. The results are consistent with the observation that splenic
perfusion was transiently and selectively lowered in tumour-bear-
ing mice following treatment with FAA (ﬂavone-8-acetic acid), a
drug related structurally to DMXAA (Honess and Bleehen, 1991).
Previous work from our laboratory has indicated the presence of
tumour-secreted factors leading to priming of tumoricidal
macrophages and their responsiveness to activation by DMXAA
(Ching et al, 1993). The procoagulant activity of human
endothelial cells in culture is strongly up-regulated by condi-
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Figure 2 Northern blots for mRNA expression. (A) mRNA for IP-10, TNF, IFN-a, IFN-g in HECPP cells detected 2 h following in vitro treatment with
DMXAA (400 mgm l
71). Loading of each lane shown by GADPH mRNA levels. Untreated controls (lane C). (B) mRNA for IP-10, TNF, IFN-a, IFN-g in
murine splenocytes detected 2 h following in vivo treatment with DMXAA (25 mg kg
71).
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cinoma cell line. The tumour conditioned medium had a greater
effect on endothelial cells than did hypoxia, reduced oxygen
tension, TNF, FAA or DMXAA (Watts et al, 1996), providing
another clear example of the priming effect of tumour secreted
factors.
The ‘priming’ effect may provide an explanation of the remark-
ably rapid onset (30 min) of apoptosis of vascular endothelial cells
in the Colon 38 tumour. It is not known whether vascular
endothelial apoptosis could occur as rapidly in human tumours,
since the earliest time point following DMXAA that we were able
to examine was 3 h. However, apoptosis occurred more rapidly
following DMXAA administration in vivo than in HECPP cells in
culture.
Clinical trials of DMXAA have indicated a low response rate to
DMXAA (Jameson et al, 2000). However, good evidence has been
provided for induced vascular effects, such as reduced tumour
blood ﬂow (Rustin et al, 1998), serotonin release (Jameson et al,
2000) and the endothelial apoptosis reported in this study. The
clinical trial results differ from those of murine studies in that
although TNF synthesis was detected in one human tumour sample
(Jameson et al, 2000) the level was low and TNF was not detected
in the sample in which endothelial cell apoptosis was observed.
Widespread haemorrhagic necrosis is a prominent effect of
DMXAA treatment in murine tumours (Baguley et al, 1989; Zwi
et al, 1994b; Cao et al, 1999) but has not so far been observed
in clinical trials. In the Colon 38 tumour, in situ TNF synthesis
(Joseph et al, 1999) is probably responsible for sustaining the
vascular effect of DMXAA and inducing haemorrhagic necrosis.
Combination of DMXAA with agents that improve intratumoural
TNF synthesis might constitute a rational approach in further clin-
ical trials of DMXAA. In cultured human peripheral blood
leucocytes, a second signal, such as that provided by trace amounts
of endotoxin or interleukin-1, is required in order for DMXAA to
induce TNF production (Philpott et al, 2001). Clinical studies
employing DMXAA in combination with other agents that provide
a second signal within tumour tissue may provide a pathway
towards improved anticancer therapy.
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dothelial cells. (A) Percentage of HECPP cells stained using TUNEL assay
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(B) Percentage TUNEL-staining HECPP cells 24 h after exposure to differ-
ent DMXAA concentrations. Mean+s.e.m. of at least three determina-
tions, obtained by counting 500 cells.
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